{"id":185713,"date":"2024-03-21T22:25:21","date_gmt":"2024-03-22T03:25:21","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2024\/03\/x-ray-activated-nanoparticles-halt-alzheimers-in-study"},"modified":"2024-03-21T22:25:21","modified_gmt":"2024-03-22T03:25:21","slug":"x-ray-activated-nanoparticles-halt-alzheimers-in-study","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2024\/03\/x-ray-activated-nanoparticles-halt-alzheimers-in-study","title":{"rendered":"X-Ray activated nanoparticles halt Alzheimer\u2019s in study"},"content":{"rendered":"<p>A novel approach in the field of Alzheimer\u2019s research is emerging that could potentially transform how we tackle this debilitating disease. Recent studies have revealed a paradigm shift in understanding Alzheimer\u2019s pathology, emphasizing the importance of targeting the early-stage aggregation of the pathogenic amyloid beta (A-beta) protein, specifically focusing on its soluble oligomeric form.<\/p>\n<p>Over the past three decades, conventional treatments for Alzheimer\u2019s have largely been ineffective, primarily due to their focus on combating the fibrillar form of A-beta. However, emerging research suggests that it is the soluble oligomeric form of A-beta that poses the greatest threat to neuronal health, leading to cognitive decline and neurotoxicity.<\/p>\n<p>A recent breakthrough in Alzheimer\u2019s treatment has come from the development of an antibody capable of recognizing both oligomeric and fibrillar forms of A-beta, offering newfound hope to the field. This innovative therapy has demonstrated promising results in delaying disease progression by up to 36% in individuals with early-to-mild cognitive impairment.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>A novel approach in the field of Alzheimer\u2019s research is emerging that could potentially transform how we tackle this debilitating disease. Recent studies have revealed a paradigm shift in understanding Alzheimer\u2019s pathology, emphasizing the importance of targeting the early-stage aggregation of the pathogenic amyloid beta (A-beta) protein, specifically focusing on its soluble oligomeric form. Over [\u2026]<\/p>\n","protected":false},"author":359,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,1495,4,47],"tags":[],"class_list":["post-185713","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-health","category-nanotechnology","category-neuroscience"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/185713","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/359"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=185713"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/185713\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=185713"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=185713"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=185713"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}